leronlimab
Sign in to saveAlso known as PA14, PRO-140, PRO 140
Leronlimab (codenamed PRO 140) is a humanized monoclonal antibody targeted against the CCR5 receptor found on T lymphocytes of the human immune system. It is being investigated as a potential therapy in the treatment of triple negative breast cancer and HIV infection.
~3 min read
Article
7 sectionsContents
- Development
- Mechanism of action
- Research
- COVID-19
- See also
- References
- External links
Leronlimab (codenamed PRO 140) is a humanized monoclonal antibody targeted against the CCR5 receptor found on T lymphocytes of the human immune system. It is being investigated as a potential therapy in the treatment of triple negative breast cancer and HIV infection.
The United States Food and Drug Administration has designated PRO 140 for fast-track approval.
Connections
tenofovir alafenamide
Entity
antiretroviral therapy for HIV/AIDS
Entity
monoclonal antibody
Entity
triple-negative breast cancer
Entity
humanized antibody
Entity
nucleoside analogue
Entity
lumiliximab
Entity
COVID-19
Entity
HIV/AIDS
Entity
immunity
Entity
HIV
Entity
public domain
Entity
breast cancer
Entity
digital object identifier
Entity
lung cancer
Entity
medical treatment
Entity
prostate cancer
Entity
Colorectal cancer
Concept
melanoma
Entity
placebo
Entity